March 22, 2024

Abstract 5067: Exploring the genomic landscape of de novo neuroendocrine prostate cancer: Insights for innovative therapies from spatial gene expression analysis

Key Points

Key points are not available for this paper at this time.

Abstract

Abstract Introduction Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 5067.

Bookmark

Cite This Study

Watanabe et al. (Fri,) studied this question.

synapsesocial.com/papers/68e72e40b6db6435876a84cf https://doi.org/https://doi.org/10.1158/1538-7445.am2024-5067

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1PD09-02 A GENETIC LANDSCAPE OF DE NOVO NEUROENDOCRINE PROSTATE CANCER AND POSSIBLE NOVEL THERAPEUTIC STRATEGIES UNVEILED BY SPATIAL GENE EXPRESSION ANALYSIS2024
2Abstract 5461: Molecular genetic profiling of a <i>de novo</i> neuroendocrine prostate cancer in a patient-derived xenograft (PDX) and organoid model from an African ancestry patient.2026
3Abstract 7688: Blood-based proteomic profiling reveals novel biomarkers of neuroendocrine prostate cancer2026
4Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer.2024
5Abstract 466: microRNA regulators of neuroendocrine differentiation in metastatic castration-resistant prostate cancer2024

Bookmark